# Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Source: https://onco.cc/trials/nct06585410/  
OnCo record `nct06585410` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cemiplimab in cutaneous squamous cell carcinoma, run by Regeneron Pharmaceuticals, now recruiting.

## Summary

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT06585410 by Regeneron Pharmaceuticals, with 369 participants planned, started 2025-01-02 and due to reach its primary completion in 2030-05-03. Interventions recorded: Cemiplimab, Standard of care. Conditions listed: Cutaneous Squamous Cell Carcinoma (CSCC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06585410
- Phase: 3
- Setting: A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC)
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 369

## Sources

- ClinicalTrials.gov NCT06585410: https://clinicaltrials.gov/study/NCT06585410

## Connected records

- cancers: [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct06585410.json